%0 Journal Article
%A Longuespée, Rémi
%A Kunz, Julia
%A Fresnais, Margaux
%A Foerster, Kathrin I
%A Burhenne, Jürgen
%A Thomas, Michael
%A Kazdal, Daniel
%A Stenzinger, Albrecht
%A Christopoulos, Petros
%A Haefeli, Walter E
%T Therapeutic drug monitoring of osimertinib in non-small cell lung cancer and short bowel syndrome: A case report.
%J British journal of clinical pharmacology
%V 90
%N 1
%@ 0306-5251
%C Oxford
%I Wiley-Blackwell
%M DKFZ-2023-02225
%P 344-349
%D 2024
%Z Case report / 2024 Jan;90(1):344-349 / #EA:B350#
%X Short bowel syndrome (SBS) following extensive intestinal resection is often characterized by impaired absorption of orally administered drugs, including tyrosine kinase inhibitors (TKI). We report the case of a patient with EGFR-mutated non-small cell lung carcinoma treated with 80 mg/day of the TKI osimertinib who achieved partial response of the tumour, but was subsequently subjected to a double-barrelled jejunostomy due to ileus. Due to the development of SBS after the bypass surgery, plasma concentrations of osimertinib were monitored using mass spectrometry. The therapeutic drug monitoring confirmed a malabsorption of osimertinib in the patient (108 ng/mL, which is below the 5th percentile of the expected plasma concentration) and was useful to guide adjustments of TKI dosing in order to achieve adequate blood levels (161 ng/mL after increase of the dose to 120 mg/day) in order to maintain tumour control.
%K LC-MS/MS (Other)
%K MALDI-MS/MS (Other)
%K non-small cell lung cancer (Other)
%K osimertinib (Other)
%K short bowel syndrome (Other)
%K therapeutic drug monitoring (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37815301
%R 10.1111/bcp.15924
%U https://inrepo02.dkfz.de/record/285101